Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
GHAPPcast
This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).
Be sure to visit the podcast's website and support the creator: ghappcast.captivate.fm
Author
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)
Category
Podcast website
Latest episode
Nov 17, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
GHAPPcast: CD64+ Binding: Description, Relevance, and Potential Clinical Implications 16.01.2025 11:56
Thank you to Johnson & Johnson for your support of this GHAPPcast episode. In this insightful episode of GHAPPcast, the official podcast of the Gastroenterology and Hepatology Advanced Practice Providers, host Gabriella McCarty, NP-C, delves into the complex yet critical topic of CD64 positive binding and its relevance in inflammatory bowel disease (IBD) treatment, particularly in relation to...
FAQ: Provide immunologic rationale for IL23 directed therapy in IBD(+ general overview of Guselkumab MOA) 14.01.2025 2:23
Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this informative FAQ video module, Sarah Enslin, a physician assistant at the University of Rochester Medical Center, discusses the role of Interleukin-23 (IL-23) in treating immune-mediated inflammatory diseases, particularly inflammatory bowel disease (IBD). Sponsored by Johnson & Johnson, this video highlights...
Journal Club: Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis 09.01.2025 5:16
Thank you to Johnson & Johnson for your support of this Journal Club Video Module. In this Journal Club video module, Shayla Scheonoff, a physician assistant from Rochester, Minnesota, provides a comprehensive review of the efficacy and safety of Guselkumab induction therapy for moderately to severely active ulcerative colitis (UC). Sponsored by Johnson & Johnson, this detailed analysis co...
Medication Review: What is non-responder imputation and how is it utilized in clinical trials? 07.01.2025 2:12
Thank you to Johnson & Johnson for your support of this Medication Review Video Module. Clinical trials play a crucial role in guiding treatment decisions, but the way missing data is handled can significantly impact the results. In this medication review video module, Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, NM, explains the concept of non-responder imputation (N...
FAQ: What is the role of IL23/IL17 axis in IBD 17.12.2024 2:21
Thank you to Johnson & Johnson for your support of this FAQ Video Module. Inflammatory Bowel Disease (IBD) is a complex condition influenced by genetic, environmental, and microbial factors. In this FAQ video module, Amy Stewart, ARNP, from Capital Digestive Care in Washington, DC, explains the critical role of the IL-23/IL-17 axis in the pathogenesis of IBD. Supported by Johnson & Johnson...
FAQ: Describe the IL23/IL17 axis 12.12.2024 2:02
Thank you to Johnson & Johnson for your support of this FAQ Video Module. Welcome to this FAQ video module, proudly supported by Johnson & Johnson. In this educational session, Erica Heagy, NP, from Alaska Digestive and Liver Disease, explores the IL-23/IL-17 axis, a crucial pathway in the pathogenesis of inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, multiple sclerosis,...
GHAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of IBD 12.12.2024 12:00
Thank you to Johnson & Johnson for your support of this GHAPPcast episode. Welcome to GHAPPcast, the official podcast of Gastroenterology and Hepatology Advanced Practice Providers (GHAPP), where we delve into the latest advancements in GI and liver diseases. In this enlightening episode, host Gabriella McCarty, NP-C, from NorthShore Gastroenterology, explores the intricate role of the IL-23/I...
Medication Review: Describe the mechanism of action of guselkumab 05.12.2024 2:12
Thank you to Johnson & Johnson for your support of this Medication Review Video Module. In this medication review, Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, New Mexico, explores the mechanism of action of Guselkumab, a promising monoclonal antibody therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). IBD is drive...
FAQ: Define, compare, and contrast humoral and cell-mediated immunity. 04.12.2024 1:46
Thank you to Johnson & Johnson for your support of this FAQ Video Module. In this FAQ video module, Erica Heagy, NP, from Alaska Digestive and Liver Disease, breaks down the key differences between humoral immunity and cell-mediated immunity, two crucial components of the adaptive immune system that protect the body from infections. Adaptive immunity is triggered when the body is exposed to an...
GHAPPcast: CSID in Adults: Clinical Pearls & the Patient Journey 14.11.2024 25:43
Live from the GHAPP National 2024 Conference, Dr. Dakesh Patel, a gastroenterologist with the GI Alliance of Illinois, joins Kate Scarlata, MPH, RD, a nationally renowned dietitian and bestselling author, and Kaitlin Colella, PA, to discuss congenital sucrase-isomaltase deficiency (CSID), a frequently overlooked digestive disorder. CSID affects the body's ability to break down sugar and starch due...
GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024 18.10.2024 2:13
Welcome back to the final installment of our three-part miniseries on Primary Biliary Cholangitis (PBC) from the GHAPP National 2024 Conference! In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss the most impactful updates in PBC management, treatment goals, and evolving clinical strategies. A major highlight from this year’s meeting is the shifting treatment...
GHAPP PBC Podcast Series Part 1: Prevalence, Awareness and Identification of PBC 18.10.2024 3:47
Welcome to Part 1 of our three-part miniseries on Primary Biliary Cholangitis (PBC), recorded live at GHAPP 2024! In this episode, Elizabeth Goacher, FNP (Duke University), Jeremy Davis, NP (Gastrointestinal Specialists, Louisiana), and Allison Moser, NP (Rush University Medical Center, Chicago) discuss the rising prevalence of PBC, increased awareness, and improved identification strategies in cl...
GHAPP PBC Podcast Series Part 2: New Therapeutics In The PBC Space 18.10.2024 5:13
Welcome back to Part 2 of our three-part Primary Biliary Cholangitis (PBC) miniseries, where we explore the latest advancements in PBC treatment and disease management. In this episode, Elizabeth Goacher, FNP, Jeremy Davis, NP, and Allison Moser, NP discuss new therapeutic options, including seladelpar and elafibranor, and how these emerging treatments are transforming the PBC landscape. With the...
KOL Conversation: New & Emerging Treatment Considerations for PBC & PBC Pruritus 15.10.2024 1:16
In this episode, Jordan Mayberry, PA-C from UT Southwestern Medical Center, discusses how newly approved therapies are transforming the management of cholestatic pruritus in Primary Biliary Cholangitis (PBC). With pruritus being one of the most challenging symptoms for PBC patients, these emerging treatments offer a targeted approach to improving patient quality of life. As PBC patients often stru...
KOL Conversation: A New Treatment Option 15.10.2024 9:21
Live from the GHAPP 2024 Conference in Washington, D.C., Dr. Renee Pozza, NP (Southern California GI & Liver Centers) and Allysa Saggese, NP (Weill Cornell Medicine, Manhattan) discuss the latest FDA-approved therapies for Primary Biliary Cholangitis (PBC) and how they fit into the evolving treatment landscape. With new medications offering both biochemical improvements and symptom relief, par...
Medication Review: What is the clinical profile of Resmetirom, including dosing schedules? 03.10.2024 2:50
Thank you to Madrigal for your support of this Medication Review Video Module. In this Medication Review Video Module, Whitney Steinmetz, NP, provides an in-depth discussion on the clinical profile of Retam (Resd) for Metabolic-Associated Steatohepatitis (MASH) with moderate to advanced F2 or F3 fibrosis. While Retam is not currently FDA-approved for patients with cirrhosis, ongoing trials are eva...
FAQ: How is MASH severity staged? What would an ideal MASH NIT algorithm look like? 03.10.2024 2:14
Thank you to Madrigal for your support of this FAQ Video Module. In this FAQ Video Module, Jonathan Yeh, PA, from Columbia University Irving Medical Center, discusses the evolution of Metabolic Dysfunction-Associated Steatohepatitis (MASH) diagnosis and fibrosis staging. Formerly known as NASH, MASH was traditionally diagnosed through liver biopsy, but non-invasive testing (NITs) is now widely acc...
FAQ: What are the consequences of NASH going untreated? 03.10.2024 3:45
Thank you to Madrigal for your support of this FAQ Video Module. In this FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, discusses the serious consequences of untreated Metabolic Dysfunction-Associated Steatohepatitis (MASH) and how Advanced Practice Providers (APPs) can play a crucial role in patient education and early inte...
Medication Review Video Module: What is Resmetirom and how does it work to treat MASH? 03.10.2024 2:52
Thank you to Madrigal for your support of this Medication Review Video Module. In this Medication Review Video Module, Robin Soto, NP, from UC San Diego Health Hepatology, provides an in-depth look at the mechanism of action of Resmetirom, the first and only FDA-approved drug for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in adults with F2, F3, or mild to moderate fib...
FAQ: What is MASH? 03.10.2024 3:12
Thank you to Madrigal for your support of this FAQ Video Module. In this FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, answers key questions about Metabolic Dysfunction-Associated Steatohepatitis (MASH)—a progressive liver disease that was previously known as Non-Alcoholic Steatohepatitis (NASH). MASH is the inflammatory fo...
Journal Club: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis 03.10.2024 4:57
Thank you to Madrigal for your support of this Journal Club Video Module. In this Journal Club Video Module, Lisa Richards, NP, a hepatology specialist with over 20 years of experience at UC San Diego Health, presents the pivotal findings of the Phase 3 randomized controlled trial of Resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with liver fibrosis. Publis...
GHAPPcast: Recognizing the Severity of MASH 03.10.2024 19:35
Thank you to Madrigal for your support of this GHAPPcast episode. In this GHAPPcast episode, Patrick Horne, NP, from the University of Florida, and April Morris, NP, from Richmond VA, discuss how to recognize the severity of MASH, identify at-risk patients, and implement early intervention strategies to prevent disease progression. MASH is strongly linked to metabolic dysfunction, making certain p...
FAQ: Best practices to accelerate the time to finding the right therapy for your patients with IBS-C? 18.09.2024 2:18
Thank you to Ardelyx for your support of this FAQ Video Module. In this FAQ Video Module, Kim Orleck, PA-C, from Atlanta Gastroenterology Associates, discusses best practices to accelerate the process of identifying the right therapy for patients with Irritable Bowel Syndrome with Constipation (IBS-C). A timely and accurate diagnosis is the foundation for effective treatment, helping reduce unnece...
FAQ: What are some best practices in determining clinically meaningful “response” to therapy for IBS-C patients? 17.09.2024 2:10
Thank you to Ardelyx for your support of this FAQ Video Module. In this episode, Kim Orleck, PA-C, discusses key strategies for evaluating treatment response in patients with IBS-C (Irritable Bowel Syndrome with Constipation). With multiple therapeutic options now available, it is essential for providers to take a patient-centered approach to ensure meaningful symptom improvement and treatment sat...
FAQ: What resources do you use to understand the latest approaches to managing IBS-C patients? 17.09.2024 1:52
Thank you to Ardelyx for your support of this FAQ Video Module. In this FAQ Video Module, Kim Orleck, PA-C, from Atlanta Gastroenterology Associates, shares the most valuable resources for staying up to date on the latest approaches to managing IBS-C patients. As treatment strategies continue to evolve, leveraging evidence-based guidelines, professional conferences, industry expertise, and peer di...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.